Among the great challenges in biology are the precise quantification of specific sets of proteins and analyses of their patterns of interaction on a much larger scale than is possible today. This thesis presents a novel protein detection technique - proximity ligation - and reports the development and application of a nucleic acid amplification technique, RCA. Proximity ligation converts information about the presence or co-localization of specific proteins to unique sets of nucleic acid sequences. For detection of target proteins or protein complexes the coincident binding by pairs or triplets of specific protein-binding reagents are required. Oligonucleotide-extensions attached to those binding reagents are joined by a DNA ligase and subsequently analyzed by standard molecular genetic techniques. The technique is shown to sensitively detect an assortment of proteins using different types of binders converted to proximity probes, including SELEX aptamers and mono- and polyclonal antibodies. I discuss factors important for using the technique to analyze many proteins simultaneously. Quantification of target molecules requires precise amplification and detection. I show how rolling circle amplification, RCA, can be used for precise quantification of circular templates using modified molecular beacons with real-time detection. The combination of proximity-probe templated circularization and RCA results in a sensitive method with high selectivity, capable of visualizing individual immobilized proteins. This technique is used for localized detection of a set of individual proteins and protein complexes at sub-cellular resolution.

Proteins are fundamental structural, enzymatic and regulatory components of cells. Analysis of proteins, such as by measuring their concentrations, characterizing their modifications, and detecting their interactions, provides insights in how biological systems work physiologically or pathologically at the molecular level. To perform such analysis, molecular tools with good sensitivity, specificity, high multiplexing and throughput capacity are needed. In this thesis, four different assays were developed and applied to detect and profile proteins and protein complexes in human body fluids, and in cells or tissues. These assays are based on targeting proteins or protein complexes by oligonucleotide-conjugated antibodies, and subsequent proximity dependent enzymatic reactions involving the attached DNA reporter sequences. In paper I, a solid-phase proximity ligation assay (SP-PLA) was applied to detect synthetic and endogenous amyloid beta protofibrils. The SP-PLA provided better sensitivity and increased dynamic range than a traditional enzyme-linked immunosorbent assay (ELISA). In paper II, in situ PLA was applied to investigate the correlation between MARK2-dependent phosphorylation of tau and Alzheimer’s disease. Greater numbers of MARK2-tau interactions and of phosphorylated tau proteins were observed in brain tissues from Alzheimer’s patients than in healthy controls. In paper III, a multiplex SP-PLA was applied to identify protein biomarker candidates in amyotrophic lateral sclerosis (ALS) disease and in the analgesic mechanism of spinal cord stimulation (SCS). Among 47 proteins in human cerebrospinal fluid (CSF) samples, four were found at significantly lower concentrations (p-values < 0.001) in the samples from ALS patients compared to those from healthy controls (follistatin, IL-1α, IL-1β, and KLK5). No significant changes of the analyzed proteins were found in the CSF samples of neuropathic pain patients in   the stimulated vs. non-stimulated condition using SCS. In paper IV, a new technology termed the proximity barcoding assay (PBA) was developed to profile individual protein complexes. The performance of PBA was demonstrated on artificially assembled streptavidin-biotin oligonucleotide complexes. PBA was also proven to be capable of profiling transcriptional pre-initiation complexes from nuclear extract of a hepatic cell line.

Intra- and intercellular information is communicated by posttranslational modifications (PTMs) and protein-protein interactions, transducing information over cell membranes and to the nucleus. A cells capability to respond to stimuli by several highly complex and dynamic signaling networks provides the basis for rapid responses and is fundamental for the cellular collaborations required in a multicellular organism. Having received diverse stimuli, being positioned at various stages of the cell cycle or, for the case of cancer, containing altered genetic background, each cell in a population is slightly different from its neighbor. However, bulk analyses of interactions will only reveal an average, but not the true variation within a population. Thus studies of interacting endogenous biomolecules in situ are essential to acquire a comprehensive view of cellular functions and communication. In situ proximity ligation assay (in situ PLA) was developed to investigate individual endogenous protein-protein interactions in fixed cells and tissues and was later applied for detection for PTMs. Progression of signals in a pathway can branch out in different directions and induce expression of different target genes. Hence simultaneous measurement of protein activity and gene expression provides a tool to determine the balance and progression of these signaling events. To obtain this in situ PLA was combined with padlock probes, providing an assay that can interrogate both PTMs and mRNA expression at a single cell level. Thereby different nodes of the signaling pathway as well as drug effects on different types of molecules could be investigated simultaneously. In addition to regulation of gene expression, protein-DNA interactions present a mechanism to manage accessibility of the genomic DNA in an inheritable manner, providing the basis for lineage commitment, via e.g. histone PTMs. To enable analyses of protein-DNA interactions in situ we developed a method that utilizes the proximity dependence of PLA and the sequence selectivity of padlock probes. This thesis presents new methods providing researchers with a set of tools to address cellular functions and communication in complex microenvironments, to improve disease diagnostics and to contribute to hopefully finding cures.

Improved analytical methods provide new opportunities for both biological research and medical applications. This thesis describes several novel molecular techniques for nucleic acid and protein analysis based on detection or sequencing of amplified single molecules (ASMs). ASMs were generated from padlock probe assay and proximity ligation assay (PLA) through a series of molecular processes. In Paper I, a simple colorimetric readout strategy for detection of ASMs generated from padlock probe assay was used for highly sensitive detection of RNA virus, showing the potential of using padlock probes in the point-of-care diagnostics. In Paper II, digital quantification of ASMs, which were generated from padlock probe assay and PLA through circle-to-circle amplification (C2CA), was used for rapid and sensitive detection of nucleic acids and proteins, aiming for applications in biodefense. In Paper III, digital quantification of ASMs that were generated from PLA without C2CA was shown to be able to improve the precision and sensitivity of PLA when compared to the conventional real-time PCR readout. In Paper IV, a non-optical approach for detection of ASMs generated from PLA was used for sensitive detection of bacterial spores. ASMs were detected through sensing oligonucleotide-functionalized magnetic nanobeads that were trapped within them. Finally, based on in situ sequencing of ASMs generated via padlock probe assay, a novel method that enabled sequencing of individual mRNA molecules in their natural context was established and presented in Paper V. Highly multiplex detection of mRNA molecules was also achieved based on in situ sequencing. In situ sequencing allows studies of mRNA molecules from different aspects that cannot be accessed by current in situ hybridization techniques, providing possibilities for discovery of new information from the complexity of transcriptome. Therefore, it has a great potential to become a useful tool for gene expression research and disease diagnostics.

Les récepteurs de l’acide rétinoïque, RARα, β et γ sont des facteurs de transcription dépendants du ligand qui contrôlent l’expression de gènes spécifiques. Cependant, il s’avère depuis peu que les RAR ont aussi des effets non-transcriptionnels extranucléaires. Durant ma thèse, j’ai observé que (1) les fibroblastes invalidés pour tous les RAR ont un cytosquelette d’actine perturbé et ont perdu leurs propriétés d’adhésion (2) RARα interagit via son motif riche en proline N-terminal avec la profiline 2a (PFN2a) qui est un régulateur critique de l’élongation des filaments d’actine du cytosquelette. J’ai montré que : (1) Les RAR contrôlent la morphologie, l’adhésion et la migration des MEF via la régulation transcriptionnelle de l’expression de gènes codant pour des protéines d’adhésion (2) Dans le cytoplasme, RARα forme avec PFN2a des complexes dont le nombre contrôle le réseau d’actine et l’adhésion des MEF via un mécanisme non transcriptionnel. Ces observations mettent en exergue l’importance de la combinaison des effets génomiques et non-génomiques des RAR dans l’adhésion des cellules et ouvrent de nouvelles possibilités de dérégulation du fonctionnement des RAR dans certaines pathologies. / Retinoic acid receptors, RARα, β and γ are ligand-dependent transcription factors that control the expression of specific genes. However, growing evidence indicates that RARs also have extranuclear and non transcriptional effects. During my thesis, I observed that (1) fibroblasts invalidated for all RARs depict a disrupted actin cytoskeleton and have lost their adhesion properties (2) RARα interacts through its N-terminal proline rich motif with profilin2a (PFN2a) a critical regulator of actin filaments elongation. I have shown that: (1) RARs control the morphology, adhesion and migration of MEFs via controlling at the transcriptional level the expression of adhesion genes (2) In the cytosol, RARα forms complexes with PFN2a. The number of these complexes controls the actin network and the adhesion of MEFs via a non-transcriptional mechanism. These observations highlight the importance of the combined genomic and non-genomic effects of RARs in cell adhesion, and open new avenues for RARs deregulations in certain pathology.

Les principales caractéristiques neuropathologiques de la maladie d’Alzheimer (MA) sont les plaques séniles extracellulaires composées de peptide amyloïde β (Aβ) et les enchevêtrements neurofibrillaires intracellulaires composés de Tau hyperphosphorylé. Les mécanismes conduisant à la formation de ces lésions sont encore peu connus et le laboratoire a récemment caractériser le gène “bridging integrator 1” (BIN1), deuxième facteur de risque génétique le plus associé au risque de MA, comme facteur de risque potentiellement associé à la pathologie Tau. Une interaction entre les deux protéines a été décrite in vitro et in vivo suggérant que BIN1 pourrait être impliqué dans le développement de la pathologie associée à Tau dans le cadre de la MA. Cependant, ce rôle de l'interaction BIN1-Tau dans le processus pathophysiologique de la MA n'est pas connu et il reste ainsi à déterminer si cette interaction constitue une cible thérapeutique potentielle. Ce projet a visé alors à mieux comprendre les acteurs de cette interaction en identifiant les modulateurs et les voies moléculaires impliquées dans le contrôle de l'interaction BIN1-Tau, puis de déterminer comment cette interaction est modulée dans le contexte de la MA. Nous avons utilisé pour cela des approches complémentaires de biochimie, de résonance magnétique nucléaire et de microscopie confocale. Comme modèle cellulaire, des cultures primaires de neurones de rat ont été utilisées, et la méthode “proximity ligation assay” (PLA) a été développée comme approche principale pour observer l'interaction BIN1-Tau dans ces cellules. Nous avons déterminé que l'interaction se produit entre les domaines SH3 de BIN1 et le PRD de Tau et nous avons démontré que l’interaction est modulée par la phosphorylation de Tau et BIN1: la phosphorylation de la Thréonine 231 de Tau diminue son interaction avec BIN1, tandis que la phosphorylation de BIN1 à la Thréonine 348 (T348) augmente son interaction avec Tau. Nous avons mis au point une approche de criblage d’haut contenu semi-automatisée et basé sur une bibliothèque de composés commerciaux. Ce criblage s’est basé sur des cultures primaires de neurones comme modèle cellulaire et le PLA pour détecter l'interaction BIN1-Tau. Nous avons identifié plusieurs composés capables de moduler l'interaction BIN1-Tau, notamment U0126, un inhibiteur de MEK-1/2, qui diminue cette interaction, et la cyclosporine A, un inhibiteur de la calcineurine, qui au contraire augmente celle-ci en augmentant la phosphorylation de T348 de BIN1. Par ailleurs les “Cyclin-dependent kinases” (CDK) ont été montré comme contrôlant aussi ce site de phosphorylation. Nous avons donc mis en évidence le couple Calcineurine/CDK comme contrôlant la phosphorylation T348 de Bin1 et donc l’interaction BIN1-Tau. Nous avons également développé un modèle murin de tauopathie dans lequel nous avons surexprimé BIN1 humain. Nous avons observé que la surexpression de BIN1 résorbait les déficits de mémoire à long terme et réduisait la présence d'inclusions intracellulaires de Tau phosphorylée, provoquées par la surexpression de Tau, ce qui était associé à une augmentation de l'interaction BIN1-Tau. En utilisant des échantillons de cerveau humain post-mortem, nous avons observé que les niveaux de l’isoforme BIN1 neuronal étaient diminués dans les cerveaux d’AD, alors que les niveaux relatifs de BIN1 phosphorylé à T348 étaient augmentés, suggérant un mécanisme compensatoire. Cette étude a démontré la complexité et la dynamique de l’interaction BIN1-Tau dans les neurones, a révélé des modulateurs et des voies moléculaires potentiellement impliquées dans cette interaction, et a montré que les variations de l’expression ou de l’activité de BIN1 ont des effets directs sur l’apprentissage et la mémoire, possiblement liés à la régulation de son interaction avec Tau. / The main neuropathological hallmarks of Alzheimer’s disease (AD) are the extracellular senile plaques composed of amyloid-β peptide (Aβ) and the intracellular neurofibrillary tangles composed of hyperphosphorylated Tau. The mechanisms leading to the formation of these lesions is not well understood and our lab has recently characterized the bridging integrator 1 (BIN1) gene, the second most associated genetic risk factor of AD and the first genetic risk factor to have a potential link to Tau pathology. The interaction between BIN1 and Tau proteins has been described in vitro and in vivo, which suggests that BIN1 might help us to understand Tau pathology in the context of AD. However, the role of BIN1-Tau interaction in the pathophysiological process of AD is not known, and whether this interaction is a potential therapeutic target remains to be determined. The aim of this project is to better understand the actors of BIN1-Tau interaction through the identification of the modulators and the molecular pathways involved therein, as well as to understand how BIN1-Tau interaction is modulated in the context of AD. We employed biochemistry, nuclear magnetic resonance, and confocal microscopy. We used rat primary neuronal cultures (PNC) as the cellular model and developed the proximity ligation assay (PLA) as the main readout of the BIN1-Tau interaction in cultured neurons. We determined that the interaction occurs between BIN1’s SH3 domain and Tau’s PRD domain, and demonstrated that it is modulated by Tau and BIN1 phosphorylation: phosphorylation of Tau at Threonine 231 decreases its interaction with BIN1, while phosphorylation of BIN1 at Threonine 348 (T348) increases its interaction with Tau. We developed a novel, semi-automated high content screening (HCS) assay based on a commercial compound library, also using PNC as the cellular model and PLA as the readout of BIN1-Tau interaction. We identified several compounds that are able to modulate the BIN1-Tau interaction, most notably U0126, an inhibitor of MEK-1/2, which reduced the interaction, and Cyclosporin A, an inhibitor of Calcineurin, which increased the interaction through increasing the BIN1 phosphorylation at T348. Furthermore, Cyclin-dependent kinases (CDK) were also shown as regulator of this phosphorylation site. These results suggest that the couple Calcineurin/CDK regulates BIN1 phosphorylation at T348 and consequently the BIN1-Tau interaction. We also developed a mouse model of tauopathy in which we overexpressed human BIN1. We observed that the overexpression of BIN1 rescued the long-term memory deficits and reduced the presence of intracellular inclusions of phosphorylated Tau, caused by Tau overexpression, and this was associated with an increase of BIN1-Tau interaction. Also, using post-mortem human brain samples, we observed that the levels of the neuronal BIN1 isoform were decreased in AD brains, whereas the relative levels of BIN1 phosphorylated at T348 were increased, suggesting a compensatory mechanism. Altogether, this study demonstrated the complexity and the dynamics of BIN1-Tau interaction in neurons, revealed modulators of and molecular pathways potentially involved in this interaction, and showed that variations in BIN1 expression or activity have direct effects on learning and memory, possibly linked to the regulation of its interaction with Tau.

In 2001 the human proteome organization (HUPO) was created with the ambition to identify and characterize all proteins encoded in the human genome according to several criteria; their expression levels in different tissues and under different conditions; the sub-cellular localization; post-translational modifications; interactions, and if possible also the relationship between their structure and function.When the knowledge of different proteins and their potential interactions increases, so does the need for methods able to unravel the nature of molecular processes in cells and organized tissues, and ultimately for clinical use in samples obtained from patients. The in situ proximity ligation assay (in situ PLA) was developed to provide localized detection of proteins, post-translational modifications and protein-protein interactions in fixed cells and tissues. Dual recognition of the target or interacting targets is a prerequisite for the creation of a circular reporter DNA molecule, which subsequently is locally amplified for visualization of individual protein molecules in single cells. These features offer the high sensitivity and selectivity required for detection of even rare target molecules. Herein in situ PLA was first established and then employed as a tool for detection of both interactions and post-translational modifications in cultured cells and tissue samples. In situ PLA was also adapted to high content screening (HCS) for therapeutic effects, where it was applied for cell-based drug screening of inhibitors influencing post-translational modifications. This was performed using primary cells, paving the way for evaluation of drug effects on cells from patient as a diagnostic tool in personalized medicine. In conclusion, this thesis describes the development and applications of in situ PLA as a tool to study proteins, post-translational modifications and protein-protein interactions in genetically unmodified cells and tissues, and for clinical interactomics.

Transport across the membrane of a cell is of crucial importance for cellular functions. The solute carrier family,SLC38 is a family of membrane proteins that transports various substances through the membrane and thusperforms many physiologically important functions, for example, transport of glutamine from astrocyte toneurons in the central nervous system. In this paper, we demonstrate that one of the transporters in this familynamed SLC38A6 forms several protein complexes with a variety of proteins in the membrane and in synapticvesicles, suggesting that SLC38A6 is involved in the synaptic release of neurotransmitters in synapses. Weperformed sensitive protein interaction analysis between the protein of interest and a variety of proteinsexpressed at different sites in the neuronal cell. We showed that SLC38A6 interacts with proteins in the cellmembrane as well as in the membrane of synaptic vesicles. The current theory is that SLC38A6 interact withthese proteins when the synaptic vesicles are in close proximity with the cell membrane during the release of theneurotransmitters.

Genomic DNA is the template of life - the entity which is characterized by a self-sustaining anatomical development, regulated signaling processes, the ability to reproduce and to respond to stimuli. Through what is classically known as the central dogma, the genome is transcribed into mRNA, which in turn is translated into proteins. The proteins take part in most, if not all, cellular processes, and it is by unraveling these processes that we can begin to understand life and disease-causing mechanisms. In vitro and in vivo assays are two levels at which protein communication may be studied, and which permit manipulation and control over the proteins under investigation. But in order to retrieve a representation of the processes as close to reality as possible, in situ analysis may instead be applied as a complement to the other two levels of study. In situ PLA offers the ability to survey protein activity in tissue samples and primary cell lines, at a single cell level, detecting single targets in their natural unperturbed environment.   In this thesis new developments of the in situ PLA are described, along with a new technique offering in situ enzyme-free detection of proximity between biomolecules. The dynamic range of in situ PLA has now been increased by several orders of magnitude to cover analogous ranges of protein expression; the output signals have been modified to offer a greater signal-to-noise ratio and to limit false-positive-rates while also extending the dynamic range further; simultaneous detection of multiple protein complexes is now possible; proximity-HCR is presented as a robust and inexpensive enzyme-free assay for protein complex detection. The thesis also covers descriptions on how the techniques may be simultaneously applied, also together with other techniques, for the multiple data-point acquisition required by the emerging realm of systems biology. A future perspective is presented for how much more information may be simultaneously acquired from tissue samples to describe biomolecular interactions in a new manner. This will allow new types of biomarkers and drugs to be discovered, and a new holistic understanding of life.

In bacteria, protein synthesis can occur tightly coupled to transcription. In eukaryotes, it is believed that translation occurs solely in the cytoplasm; I test whether some occurs in nuclei and find: (1) L-azidohomoalanine (Aha) – a methionine analogue (detected by microscopy after attaching a fluorescent tag using ‘click’ chemistry) – is incorporated within 5 s into nuclei in a process sensitive to the translation inhibitor, anisomycin. (2) Puromycin – another inhibitor that end-labels nascent peptides (detected by immuno-fluorescence) – is similarly incorporated in a manner sensitive to a transcriptional inhibitor. (3) CD2 – a non-nuclear protein – is found in nuclei close to the nascent RNA that encodes it (detected by combining indirect immuno-labelling with RNA fluorescence in situ hybridization using intronic probes); faulty (nascent) RNA is destroyed by a quality-control mechanism sensitive to translational inhibitors. I conclude that substantial translation occurs in the nucleus, with some being closely coupled to transcription and the associated proof-reading. Moreover, most peptides made in both the nucleus and cytoplasm are degraded soon after they are made with half-lives of about one minute. I also collaborated on two additional projects: the purification of mega-complexes (transcription ‘factories’) containing RNA polymerases I, II, or III (I used immuno-fluorescence to confirm that each contained the expected constituents), and the demonstration that some ‘factories’ specialize in transcribing genes responding to tumour necrosis factor α – a cytokine that signals through NFκB (I used RNA fluorescence in situ hybridization coupled with immuno-labelling to show active NFκB is found in factories transcribing responsive genes).